Pharmacotherapy for Allergic Rhinitis

Pharmacotherapy for Allergic Rhinitis - Sniffle Stoppers Intro

• Allergic Rhinitis (AR): Inflammation of nasal mucous membranes.

  ⭐ Allergic Rhinitis is an IgE-mediated inflammation of nasal mucous membranes.

• ARIA Classification (Allergic Rhinitis and its Impact on Asthma):
  • Intermittent: Symptoms <4 days/week OR <4 consecutive weeks.
  • Persistent: Symptoms >4 days/week AND >4 consecutive weeks.
  • Severity: Mild (no Quality of Life [QoL] impact) vs. Moderate-Severe (QoL impaired: sleep, daily activities, work/school).
• Pharmacotherapy Goals:
  • Control symptoms (e.g., sneezing, rhinorrhea, nasal congestion, itching).
  • Improve Quality of Life (QoL).
  • Prevent complications (e.g., sinusitis, Otitis Media with Effusion [OME]).

Pharmacotherapy for Allergic Rhinitis - Nose Ninjas & H1 Blockers

Intranasal Corticosteroids (INCS): Most effective for AR.

• Examples: 📌 FLy MoM BUys Nasal Steroids: Fluticasone, Mometasone, Budesonide.
• MOA: Broad anti-inflammatory; ↓ multiple mediators.
• Onset: Hours to days; full effect in 1-2 weeks.
• Side Effects: Local (irritation, epistaxis).

⭐ Intranasal corticosteroids are the most effective monotherapy for moderate-severe persistent Allergic Rhinitis.

H1-Antihistamines:

• Types:
  • Oral 2nd Gen (preferred): Cetirizine, Loratadine, Fexofenadine, Bilastine. (Avoid 1st Gen: Diphenhydramine - sedation).
  • Intranasal: Azelastine, Olopatadine (rapid onset).
• MOA: Block H1 receptors.
• Efficacy: Good for sneezing, itching, rhinorrhea.
• SEs: Minimal (2nd Gen oral); bitter taste (intranasal).

Comparison: INCS vs. Antihistamines (Oral 2nd Gen)

Pharmacotherapy for Allergic Rhinitis - Symptom Sidekicks

• Leukotriene Receptor Antagonists (LTRAs)

  • E.g., Montelukast.
  • MOA: Block cysteinyl leukotriene receptors.
  • Role: Allergic Rhinitis (AR), especially effective when co-existing with asthma.

  ⭐ Montelukast is particularly useful in patients with comorbid asthma and allergic rhinitis.

• Decongestants: Rapid symptom relief via vasoconstriction.

  • Oral (e.g., Pseudoephedrine): Systemic effects possible.
  • Topical (e.g., Oxymetazoline, Xylometazoline):
    • Rapid, potent local effect.
    • ⚠️ Caution: Risk of Rhinitis Medicamentosa (rebound congestion) if used for more than 3-5 days.

• Mast Cell Stabilizers

  • E.g., Sodium Cromoglicate.
  • MOA: Prevents mast cell degranulation. 📌 'CROM'oglycate - prevents degranulation.
  • Use: Prophylactic; good safety profile, especially in children.

• Intranasal Anticholinergics

  • E.g., Ipratropium bromide.
  • MOA: Anti-muscarinic; reduces glandular secretion.
  • Use: Primarily for controlling severe rhinorrhea (runny nose).

• Combination Therapies

  • E.g., Intranasal Corticosteroids (INCS) + Intranasal Antihistamine (azelastine).
  • Benefit: Synergistic effect, providing enhanced efficacy for moderate-to-severe symptoms unresponsive to monotherapy.

Pharmacotherapy for Allergic Rhinitis - Rhinitis Roadmap

ARIA guidelines advocate a stepwise approach for Allergic Rhinitis (AR) management.

• Special Populations:
  • Pregnancy: Budesonide INCS (Category B), Loratadine/Cetirizine preferred.
  • Lactation: INCS, Loratadine, Cetirizine generally safe.
  • Children: Age-appropriate INCS, OAH (e.g., Cetirizine, Levocetirizine, Fexofenadine).
  • Elderly: Caution with sedating antihistamines & decongestants.

⭐ Budesonide (Category B) is often the preferred intranasal corticosteroid during pregnancy.

Step-up if symptoms uncontrolled; step-down if controlled for ≥3 months. 📌 Manage AR Systematically!

High‑Yield Points - ⚡ Biggest Takeaways

• Intranasal corticosteroids (INCS): most effective first-line for moderate-to-severe allergic rhinitis.
• Second-gen H1-antihistamines: preferred over first-gen due to minimal sedation (e.g., loratadine).
• Oral decongestants: provide rapid relief; nasal forms risk rhinitis medicamentosa (e.g., oxymetazoline).
• Montelukast (LTRA): useful adjunct, especially with coexisting asthma.
• Cromolyn sodium: mast cell stabilizer, safe but less potent, requires frequent dosing.
• Ipratropium bromide nasal: targets and reduces cholinergic rhinorrhea.
• Omalizumab (anti-IgE): for severe, refractory allergic rhinitis and asthma.